Evidence map›Paper›PMID 42256631›Full record

ReviewJournal of scleroderma and related disorders2026

Scleroderma Clinical Trials Consortium (SCTC) outcome instruments for evaluation of systemic sclerosis.

Antonia Valenzuela, Lorinda Chung, John D Pauling, Robyn Domsic, Lesley Saketkoo, Kim Fligelstone, Anne-Marie Russell, Dinesh Khanna, Tracy Frech, Laura Ross and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of scleroderma and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Antonia ValenzuelaRheumatology and Clinical Immunology, Pontificia Universidad Catolica de Chile, Santiago de Chile, Santiago Metropolitan Region, Chile.ORCID https://orcid.org/0000-0003-3357-9402
Lorinda ChungStanford University School of Medicine, Stanford, California, USA.
John D PaulingDepartment of Rheumatology, NHS North Bristol NHS Trust, Bristol, UK.ORCID https://orcid.org/0000-0002-2793-2364
Robyn DomsicDivision of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Lesley SaketkooMedicine, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, Louisiana, USA.ORCID https://orcid.org/0000-0002-1878-8591
Kim FligelstonePatient Research Partner, London, UK.
Anne-Marie RussellBirmingham City University School of Health Sciences, Birmingham, UK.
Dinesh KhannaUniversity of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0001-6822-3401
Tracy FrechDivision of Rheumatology and Immunology, Vanderbilt University, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0002-5472-3840
Laura RossUniversity of Melbourne VCCC, Parkville, Victoria, Australia.
Mandana NikpourThe University of Sydney School of Public Health, Sydney, New South Wales, Australia.
Christopher DentonDivision of Medicine, University College London Medical School, London, UK.ORCID https://orcid.org/0000-0003-3975-8938
Murray BaronSir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Scleroderma Clinical Trials Consortium (SCTC) is committed to advancing the understanding and treatment of systemic sclerosis (SSc). This review focuses on the development and validation of various outcome instruments by the SCTC, which are crucial for evaluating the effectiveness of interventions in clinical trials and observational studies. Key instruments discussed include the Assessment of Systemic Sclerosis-Associated RAynaud's Phenomenon Questionnaire, the SCTC Radiologic Scoring System for calcinosis, the Mawdsley Questionnaire for calcinosis, the University of California Los Angeles SCTC Gastrointestinal Tract Instrument (GIT) 2.0, the SCTC Activity Index and the SCTC Damage Index. Additionally, the SCTC and World Scleroderma Foundation (WSF) Skin Scoring Certification is highlighted as an important resource for researchers. Each instrument's purpose, description and validation process are examined, underscoring their pivotal role in advancing SSc research and improving patient outcomes.

Indexed as

Outcome Assessment, Health CarePatient Reported Outcome MeasuresRandomized Controlled TrialsSeverity of Illness Index

Identifiers

PMID42256631
PMCPMC13231724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.